LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Akciju saraksts・iRhythm Technologies Inc

iRhythm Technologies Inc

Atvērts

SektorsVeselības aprūpe

113.45 -3.04

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

113.41

Max

118.53

Galvenie mērījumi
By Trading Economics
Ienākumi	-20M -14M
Pārdošana	-9.5M 199M
EPS	-0.35
Peļņas marža	-6.988
Darbinieki	2,400
EBITDA	-21M -5.3M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+52.06% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 30. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-299M 3.8B
Iepriekšējā atvēršanas cena	116.49
Iepriekšējā slēgšanas cena	113.45

Ziņu noskaņojums

By Acuity

50%

150 / 346 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

104.78 / 137.91 Atbalsts un pretestība

iRhythm Technologies Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. maijs 22:50 UTC

Peļņas

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

2026. g. 12. maijs 22:49 UTC

Peļņas

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

2026. g. 12. maijs 22:32 UTC

Peļņas

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

2026. g. 12. maijs 23:48 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

2026. g. 12. maijs 22:57 UTC

Tirgus saruna

Peļņas

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

2026. g. 12. maijs 22:26 UTC

Peļņas

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

2026. g. 12. maijs 22:25 UTC

Peļņas

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

2026. g. 12. maijs 22:25 UTC

Peļņas

Aristocrat Leisure Interim Dividend A$0.50/Security

2026. g. 12. maijs 22:24 UTC

Peļņas

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

2026. g. 12. maijs 22:23 UTC

Peļņas

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

2026. g. 12. maijs 22:23 UTC

Peļņas

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

2026. g. 12. maijs 22:19 UTC

Peļņas

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

2026. g. 12. maijs 22:14 UTC

Peļņas

CBA: Business Lending Continued to Grow Above System>CBA.AU

2026. g. 12. maijs 22:14 UTC

Peļņas

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

2026. g. 12. maijs 22:13 UTC

Peļņas

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

2026. g. 12. maijs 22:12 UTC

Peļņas

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

2026. g. 12. maijs 22:12 UTC

Peļņas

CBA 3Q New Home Loan Funding A$45B>CBA.AU

2026. g. 12. maijs 22:11 UTC

Peļņas

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

2026. g. 12. maijs 22:11 UTC

Peļņas

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

2026. g. 12. maijs 22:10 UTC

Peļņas

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

2026. g. 12. maijs 22:09 UTC

Peļņas

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

2026. g. 12. maijs 22:09 UTC

Peļņas

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

2026. g. 12. maijs 22:08 UTC

Peļņas

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

2026. g. 12. maijs 22:07 UTC

Peļņas

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

2026. g. 12. maijs 22:06 UTC

Peļņas

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

2026. g. 12. maijs 22:06 UTC

Peļņas

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

2026. g. 12. maijs 22:05 UTC

Peļņas

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Salīdzinājums

Cenas izmaiņa

iRhythm Technologies Inc Prognoze

Cenas mērķis

By TipRanks

52.06% augšup

Prognoze 12 mēnešiem

Vidējais 179.9 USD 52.06%

Augstākais 255 USD

Zemākais 147 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi iRhythm Technologies Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam iRhythm Technologies Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

104.78 / 137.91Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Noskaņojums

By Acuity

150 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.